EC approves AstraZeneca’s Soliris to treat refractory gMG in children, adolescents
The first-in-class C5 complement inhibitor, Soliris has been indicated for anti-acetylcholine receptor antibody-positive children and adolescents aged six to 17 years. It is claimed to be the first